Kerusso Capital Management LLC Grows Stock Position in Gilead Sciences, Inc. $GILD

Kerusso Capital Management LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 31.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 43,720 shares of the biopharmaceutical company’s stock after purchasing an additional 10,421 shares during the period. Gilead Sciences accounts for 2.5% of Kerusso Capital Management LLC’s investment portfolio, making the stock its 6th largest holding. Kerusso Capital Management LLC’s holdings in Gilead Sciences were worth $5,366,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of GILD. Massachusetts Financial Services Co. MA increased its stake in shares of Gilead Sciences by 3,763.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares in the last quarter. First Trust Advisors LP lifted its stake in shares of Gilead Sciences by 154.3% during the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock valued at $342,910,000 after buying an additional 1,874,508 shares in the last quarter. Invesco Ltd. boosted its holdings in Gilead Sciences by 12.0% in the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after buying an additional 1,618,453 shares during the period. Los Angeles Capital Management LLC boosted its holdings in Gilead Sciences by 46.7% in the 3rd quarter. Los Angeles Capital Management LLC now owns 3,845,379 shares of the biopharmaceutical company’s stock worth $426,837,000 after buying an additional 1,223,895 shares during the period. Finally, Danske Bank A S purchased a new stake in Gilead Sciences in the 3rd quarter worth $133,049,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on GILD shares. Daiwa Securities Group raised their price target on Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Wells Fargo & Company upped their price objective on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Mizuho increased their target price on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Sanford C. Bernstein reissued an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a research note on Wednesday, February 11th. Finally, TD Cowen boosted their price target on Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $157.35.

Gilead Sciences Stock Up 0.6%

Shares of GILD stock opened at $133.64 on Friday. The stock has a market cap of $165.88 billion, a P/E ratio of 19.74, a PEG ratio of 1.76 and a beta of 0.39. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The company’s fifty day simple moving average is $142.93 and its two-hundred day simple moving average is $131.90.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts predict that Gilead Sciences, Inc. will post 8.63 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 48.45%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the transaction, the chief financial officer owned 176,191 shares in the company, valued at $24,835,883.36. This trade represents a 1.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the sale, the chief executive officer directly owned 613,912 shares in the company, valued at approximately $92,086,800. The trade was a 15.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 178,640 shares of company stock valued at $26,691,550. Insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.